Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

For decades now, Google has been the unquestioned champion of search—our digital oracle, the first and last stop for every question, from “What’s the best pizza place near me?” to “How many protons ...

You can now search for files through the Copilot app. The new search requires a Copilot+ PC and Windows 11 insider access. The feature works by scanning the files in your Recents folder. Follow ZDNET: ...

Mandatory AI summaries have come to Google, and they gleefully showcase hallucinations while confidently insisting on their truth. I feel about them the same way I felt about mandatory G+ logins when ...

I am seeing numerous tests now that seem to prove that OpenAI's ChatGPT search feature is using Google Search's index or search results page to serve its own search results. First, Abhishek Iyer ...

The Web Guide test uses Gemini to divide, curate, and explain your search results across AI-generated categories. The Web Guide test uses Gemini to divide, curate, and explain your search results ...

Google Search can now call local businesses using AI to gather pricing and availability info on your behalf. Here's how it works. Google Search can now make AI-powered calls to local businesses.

Rallybio has swerved away from its Recursion Pharmaceuticals pact, accepting $7.5 million upfront for its share of a preclinical program to extend its cash runway to mid-2027. Exscientia, now part of ...